easy, fast...
|
|
Type
|
Public |
---|---|
Traded as | NYSE: MED S&P 600 Component |
Industry | Weight loss |
Founded | 1980 |
Headquarters | Owings Mills, Maryland, United States |
Key people
|
Daniel R. Chard, CEO |
Products | Medifast diet |
Revenue | US$ 285.3 million (2014) |
Operating income
|
US$ 30.2 million (2014) |
Net income
|
US$ 13.2 million (2014) |
Total assets | US$ 115.9 million (2014) |
Total equity | US$ 80.5 million (2014) |
Number of employees
|
808 (2014) |
Website | www |
Medifast, Inc. is an American nutrition and weight loss company based in Owings Mills, Maryland. The company owns five subsidiaries: Jason Pharmaceuticals, Inc. (Jason), Take Shape for Life, Inc. (TSFL), Jason Enterprises, Inc., Jason Properties, LLC and Seven Crondall, LLC. Medifast produces, distributes, and sells weight loss and other health-related products through websites, multi-level marketing, telemarketing, franchised weight loss clinics, and medical professionals.
The company is public with a market capitalization of $405 million, as of October 2014.
Medifast was founded in 1980 by William Vitale, a medical doctor. His products were sold directly to other doctors, who in turn prescribed them to their patients.
The company is publicly traded on the New York Stock Exchange (symbol: MED).
On July 17, 1995, HealthRite (predecessor of Medifast) changed its name from Vitamin Specialties Corp.
In October 2010, Medifast was ranked number 1 on Forbes magazine's list of "America's 100 Best Small Companies". The company was ranked 18th as of the 2014 list.
In September 2012, Medifast's subsidiary, Jason Pharmaceuticals, paid a $3.7 million USD civil penalty for false advertising. The Federal Trade Commission and United States Department of Justice said that advertisements for the "Medifast 5 & 1 Plan" low-calorie diet told consumers they could "lose up to 2-5 pounds per week.", and that these weight-loss claims lacked a reasonable scientific basis, and were unsubstantiated. Under the settlement, any future claims made by the company must be backed by at least one human clinical study.
Period | Date | Adjusted Actuals EPS | GAAP EPS |
---|---|---|---|
Q3 2022 | 2022-11-02 | Future report Set alerts | |
Q2 2022 | 2022-08-03 | 3.42 | 3.42 |
Q1 2022 | 2022-05-02 | 3.59 | 3.59 |
Q4 2021 | 2022-02-23 | 2.91 | 2.91 |
Q3 2021 | 2021-11-04 | 0.00 | 0.00 |
Q2 2021 | 2021-08-04 | 3.96 | 3.96 |
Q1 2021 | 2021-05-04 | 3.46 | 3.46 |
Q4 2020 | 2021-02-25 | 2.36 | 2.36 |
Q3 2020 | 2020-11-02 | 2.91 | 2.91 |
Q2 2020 | 2020-08-05 | 1.96 | 1.86 |
2016-01-29 | Initiated Coverage | Wunderlich | Hold to Hold | $32.00 |
2016-01-11 | Upgrade | Sidoti | Neutral to Buy | $35.00 |
2015-11-30 | Downgrade | Sidoti | Buy to Neutral | |
2015-11-08 | Reiterated Rating | Canaccord Genuity | Hold | $33.00 |
2015-10-15 | Reiterated Rating | Canaccord Genuity | Hold | $31.00 |
2015-10-05 | Upgrade | Sidoti | Neutral to Buy | $33.00 |
2015-05-08 | Initiated Coverage | Canaccord Genuity | Hold | $34.00 |
2015-03-15 | Reiterated Rating | Canaccord Genuity | Hold | $33.00 |
2014-11-07 | Downgrade | Imperial Capital | Outperform to In-Line | $34.00 to $32.00 |
2014-11-06 | Reiterated Rating | Canaccord Genuity | Hold | $29.00 to $30.00 |
2014-08-29 | Boost Price Target | Wedbush | Outperform | $32.00 to $36.00 |
2014-08-08 | Lower Price Target | Canaccord Genuity | $32.00 to $29.00 | |
2014-08-08 | Lower Price Target | Wedbush | $37.00 to $32.00 | |
2014-08-08 | Lower Price Target | Imperial Capital | Outperform | $36.00 to $34.00 |
2014-06-12 | Boost Price Target | Canaccord Genuity | Hold | $31.00 to $32.00 |
2014-05-06 | Lower Price Target | Canaccord Genuity | $32.00 to $31.00 | |
2014-04-23 | Boost Price Target | Imperial Capital | Outperform | $30.00 to $36.00 |
2014-03-13 | Reiterated Rating | Imperial Capital | Buy | |
2013-11-06 | Lower Price Target | Wedbush | Outperform | $35.00 to $30.00 |
2013-11-06 | Lower Price Target | Janney Montgomery Scott | Neutral | $27.00 to $25.00 |
2013-11-06 | Lower Price Target | Canaccord Genuity | Hold | $30.00 to $27.00 |
2012-11-06 | Reiterated | Northland Securities | Outperform | $29 to $34 |
2012-01-30 | Initiated | Standpoint Research | Buy | $24 |
2011-11-07 | Downgrade | Canaccord Genuity | Buy to Hold | |
2011-06-21 | Reiterated | Northland Securities | Outperform | $29 to $32 |
2011-04-01 | Reiterated | Northland Securities | Outperform | $44 to $29 |
2010-08-05 | Reiterated | Northland Securities | Outperform | $37 to $44 |
2010-05-06 | Reiterated | Northland Securities | Outperform | $35 to $37 |
2008-08-13 | Initiated | Northland Securities | Outperform | $10 |
2008-03-17 | Reiterated | Canaccord Adams | Hold | $5 to $4.50 |
2007-11-09 | Reiterated | Canaccord Adams | Hold | $7 to $5 |
2007-03-22 | Initiated | First Albany | Neutral | |
2007-01-19 | Initiated | BB&T Capital Mkts | Buy | $16 |
2016-01-29 | Initiated Coverage | Wunderlich | Hold to Hold | $32.00 |
2016-01-11 | Upgrade | Sidoti | Neutral to Buy | $35.00 |
2015-11-30 | Downgrade | Sidoti | Buy to Neutral | |
2015-11-08 | Reiterated Rating | Canaccord Genuity | Hold | $33.00 |
2015-10-15 | Reiterated Rating | Canaccord Genuity | Hold | $31.00 |
There is presents forecasts of rating agencies and recommendations for investors about this ticker
In MED 200 funds of 2213 total. Show all
Fund name | Ticker shares |
---|---|
BlackRock Inc. | 2.00M |
Vanguard Group, Inc | 1.58M |
BlackRock Fund Advisors | 0.88M |
RENAISSANCE TECHNOLOGIES LLC | 0.68M |
STATE STREET CORP | 0.38M |
BlackRock Institutional Trust Company, N.A. | 0.35M |
DIMENSIONAL FUND ADVISORS LP | 0.34M |
MORGAN STANLEY | 0.28M |
RICE HALL JAMES & ASSOCIATES, LLC | 0.27M |
PRINCIPAL FINANCIAL GROUP INC | 0.24M |
GEODE CAPITAL MANAGEMENT, LLC | 0.22M |
Numeric Investors LLC | 0.22M |
TEACHERS ADVISORS INC | 0.16M |
Lombard Odier Asset Management (Switzerland) SA | 0.15M |
CITADEL ADVISORS LLC | 0.14M |
Name Relationship | Total Shares | Holding stocks |
---|---|---|
ModusLink Global Solutions Inc | 9.38% (1194891) | MED / |
MACDONALD BRADLEY T | 4.55% (579521) | MED / |
SHEETZ GUY Executive Vice President | 3.22% (410430) | MED / |
MCDEVITT MICHAEL S Chief Executive Officer | 2.67% (340012) | MED / |
SHEETZ MARGARET MACDONALD President and COO | 2.57% (327346) | MED / |
MACDONALD MICHAEL C | 2.47% (314188) | MED / |
CONNORS BRENDAN VP Finance | 0.72% (91484) | MED / |
LAW RICHARD J Corporate Secretary | 0.49% (62081) | MED / |
CONNOLLY CHARLES P | 0.32% (41374) | MED / |
LAVIN GEORGE | 0.19% (24785) | MED / |
ROBINSON TIMOTHY G Chief Financial Officer | 0.19% (24708) | MED / |
Welling Glenn W. | 0.18% (22380) | HAIN / JMBA / MED / ROVI / |
GROVES JASON L | 0.17% (21697) | MED / |
MILLS JEANNETTE M | 0.16% (20116) | MED / |
MCDANIEL JOHN P | 0.14% (18289) | FMAR / MED / WRE / |
BROWN JEFFREY J | 0.14% (18135) | MED / OUTR / RCAP / RCII / |
MAGUIRE CATHERINE T | 0.12% (15074) | MED / |
WILLIAMS LEO Executive Vice President | 0.12% (15000) | MED / |
BONDROFF BARRY B | 0.11% (14533) | FMAR / MED / |
Chard Daniel R Chief Executive Officer | 0.11% (13920) | MED / NUS / |
SASSANO CARL E | 0.10% (12820) | IEC / MED / TRNS / |
TRAVIS MARY T Former Board member | 0.10% (12583) | MED / |
AMELI MEHRNAZ MONA President | 0.08% (10809) | MED / |
HARTWIG JORGENE K. | 0.08% (9808) | MED / |
BYRNES KEVIN G | 0.07% (9375) | BYBK / MED / |
REECE JERRY D | 0.07% (8792) | MED / |
BARNUM HARVEY C JR | 0.07% (8742) | MED / |
HALLQUIST CONSTANCE J. | 0.06% (7373) | MED / |
SCHLACKMAN SCOTT | 0.05% (7001) | MED / |
GOULD DONALD Executive Vice President | 0.05% (6804) | MED / |
UPHOUSE JEANNE M Executive Vice President | 0.03% (3804) | MED / |
VIETRI DOMINICK Executive Vice President | 0.03% (3804) | MED / |
KAGEN BRIAN Executive Vice President | 0.03% (3804) | MED / |
LLOYD BRIAN Executive Vice President | 0.01% (1865) | MED / |